X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is approved in combination with axitinib for the treatment of renal carcinoma.
Lead Product(s): Toripalimab,Axitinib
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is under phase 3 clinical development for the treatment of advanced triple-negative breast cancer.
Lead Product(s): Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
The collaboration aims to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi), supplied by Coherus, as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC).
Lead Product(s): INO-3112,Toripalimab
Therapeutic Area: Oncology Product Name: INO-3112
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is under phase 3 clinical development for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC).
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC approved for pivotal clinical study. The multiple ongoing clinical studies include more than 10 different solid tumors, evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity.
Lead Product(s): 9MW2821,Toripalimab
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is being developed for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
Loqtorzi (toripalimab-tpzi) is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity. It is approved for treatment of recurrent/metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Cisplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
The agreement aims to accelerate LBL-007, a novel antibody targeting the LAG-3 pathway, development and manufacturing for speedy clinical advancement for solid tumors.
Lead Product(s): LBL-007,Toripalimab
Therapeutic Area: Oncology Product Name: LBL-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leads Biolabs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 30, 2023
Details:
JS004/TAB004 (tifcemalimab) is the world’s first-in-human recombinant humanized anti-BTLA (B- and T-lymphocyte attenuator) monoclonal antibody and in combination with toripalimab for patients with limited-stage small cell lung cancer.
Lead Product(s): Tifcemalimab,Toripalimab
Therapeutic Area: Oncology Product Name: JS004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
The collaboration aims to develop and commercialize Tuoyi, the anti-PD-1 monoclonal antibody in 21 countries. In China, Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®).
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: $728.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2023
Details:
The collaboration aims for the development of novel masked antibody-drug conjugate (ADC) candidates, including ADG126 leveraging Adagene’s proprietary SAFEbody precision masking technology.
Lead Product(s): ADG126,Toripalimab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration May 04, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands and for enhanced receptor endocytosis function. It is being studied for advanced renal cell carcinoma.
Lead Product(s): Toripalimab,Axitinib
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 mAb which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands and for enhanced receptor endocytosis function. It is being investigated for Resectable stage III non-small cell lung cancer.
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
The two companies will collaborate to develop and commercialize Tuoyi (toripalimab), an anti-PD-1 monoclonal antibody in 9 Southeast Asian countries through a joint venture company, Excellmab.
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rxilient Biotech
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody that blocks PD-L1 binding to its receptor that minimizes opportunities for the tumor cell to evade the immune system and decreases PD-1’s expression on the T-cell restoring the body’s immune response.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 26, 2022
Details:
JS001 (toripalimab), is an anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site that minimizes opportunities for the tumor cell to evade the immune system and decreases PD-1’s expression on the T-cell.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2022
Details:
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Paclitaxel,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for multiple indications.
Lead Product(s): YH003,Toripalimab
Therapeutic Area: Oncology Product Name: YH003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ISU ABXIS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 31, 2022
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Toripalimab (tuoyi) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Porustobart (HBM4003) is fully human anti-CTLA-4 heavy chain antibody entered into clinical stage globally, enhancing antibody-dependent cell cytotoxicity killing activity, demonstrates significantly improved depletion of high CTLA-4 expressing Treg cells in tumor tissues.
Lead Product(s): Porustobart,Toripalimab
Therapeutic Area: Oncology Product Name: HBM4003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
GFH018 is an orally administered TGF-β R1 inhibitor and entered into phase I clinical trial in 2019. Preclinical data showed evidence of GFH018's good anti-tumor properties against cancer cells in vivo and in vitro.
Lead Product(s): GFH018,Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: GFH018
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2022
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, TAB004 (icatolimab), for the treatment of lymphoma and solid tumors.
Lead Product(s): Icatolimab,Toripalimab
Therapeutic Area: Oncology Product Name: TAB004
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The data for ATG-008 (Onatasertib), are based on 21 efficacy evaluable patients of 28 patients with advanced solid tumors enrolled in dose-escalation and dose-expansion phases. No dose-limiting toxicities were reported in the dose-escalation phase.
Lead Product(s): Onatasertib,Toripalimab
Therapeutic Area: Oncology Product Name: ATG-008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
In a Phase 1 clinical trial of uliledlimab in combination with atezolizumab (Tecentriq®), uliledlimab (TJ004309) was well tolerated with encouraging efficacy signals in heavily treated cancer patients (ORR=23%, DCR=46%) as presented at ASCO 2021.
Lead Product(s): Uliledlimab,Toripalimab
Therapeutic Area: Oncology Product Name: TJ004309
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Approval of sNDA is based on results from JUPITER-06 study, showed that, compared with chemotherapy alone, JS001 (toripalimab) in combination with TP chemotherapy demonstrated a statistically significant increase in survival benefits, with median overall survival.
Lead Product(s): Toripalimab,Paclitaxel,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally.
Lead Product(s): HBM4003,Toripalimab
Therapeutic Area: Oncology Product Name: HBM4003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
Toripalimab, PD-1 inhibitor, has demonstrated a compelling clinical profile in studies across multiple tumor types and is currently approved in China for four indications.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).
Lead Product(s): Toripalimab,Etoposide
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
In final PFS analysis, results from JUPITER-02 demonstrated that toripalimab in combination with chemotherapy provided a statistically significant improvement in PFS assessed by BIRC compared to chemotherapy plus placebo, with an improvement in median PFS of 13.2 months.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
CHS-006 (anti-TIGIT antibody) is being evaluated in an ongoing clinical trial in combination with toripalimab, PD-1 inhibitor for treatment of several solid tumor indications.
Lead Product(s): CHS-006,Toripalimab
Therapeutic Area: Oncology Product Name: CHS-006
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
JS001 (toripalimab), an anti-PD-1 monoclonal antibody plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone.
Lead Product(s): Toripalimab,Undisclosed
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
JUPITER-06 achieved the co-primary endpoints of progression free survival and overall survival with statistically significant and clinically meaningful improvements for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone.
Lead Product(s): Toripalimab,Paclitaxel,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
The first stage of the study is a dose escalation phase to determine the dose limiting toxicity (DLT) and recommended Phase II dose (“RP2D”) of HMPL-453 in combination with chemotherapy (gemcitabine and cisplatin) or toripalimab.
Lead Product(s): HMPL-453,Toripalimab
Therapeutic Area: Oncology Product Name: HMPL-453
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2022
Details:
Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the United States and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement.
Lead Product(s): JS006,Toripalimab
Therapeutic Area: Oncology Product Name: JS006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $290.0 million Upfront Cash: $35.0 million
Deal Type: Collaboration January 10, 2022
Details:
A tranche, will become available subject to certain conditions including approval by the U.S. FDA of the biologics license application for Coherus’ PD-1 inhibitor, toripalimab (JS001), for nasopharyngeal carcinoma, currently under review with a target action in April 2022.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pharmakon Advisors
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 07, 2022
Details:
Under the terms of the agreement, BeiGene will gain the rights for research, development and manufacturing and exclusive commercialization outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.
Lead Product(s): LBL-007,Toripalimab
Therapeutic Area: Oncology Product Name: LBL-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $772.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration December 14, 2021
Details:
Sulanda (Surufatinib), a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors and fibroblast growth factor receptor.
Lead Product(s): Surufatinib,Toripalimab,Etoposide
Therapeutic Area: Oncology Product Name: Sulanda
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Details:
SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA), a novel, oral angio-immuno kinase inhibitor in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma.
Lead Product(s): Surufatinib,Toripalimab
Therapeutic Area: Oncology Product Name: Sulanda
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
